阳性非小细胞肺癌-话题@MedSci

#阳性非小细胞肺癌#

40篇内容 | 1438人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2045858, encodeId=73ed204585888, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究, objectType=article, longId=216851, objectId=7b11216851b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b11216851b9, replyNumber=0, likeNumber=72, createdTime=2021-10-19, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b11216851b9, moduleTitle=JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b11216851b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045857, encodeId=ef5c204585e96, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, objectType=article, longId=213493, objectId=fdd621349391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd621349391, replyNumber=0, likeNumber=81, createdTime=2021-08-14, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd621349391, moduleTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdd621349391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045856, encodeId=d7ad204585607, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者, objectType=article, longId=208126, objectId=a66d208126c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d208126c5, replyNumber=0, likeNumber=67, createdTime=2021-04-30, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d208126c5, moduleTitle=优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66d208126c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045853, encodeId=563c20458533c, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, objectType=article, longId=200381, objectId=9ed320038179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed320038179, replyNumber=0, likeNumber=79, createdTime=2021-06-30, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed320038179, moduleTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed320038179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045855, encodeId=79882045855ec, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, objectType=article, longId=206520, objectId=2862206520fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2862206520fd, replyNumber=0, likeNumber=89, createdTime=2021-03-02, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2862206520fd, moduleTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2862206520fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045852, encodeId=f992204585230, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, objectType=article, longId=199973, objectId=8ec51999e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ec51999e38c, replyNumber=0, likeNumber=75, createdTime=2021-02-10, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ec51999e38c, moduleTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ec51999e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045854, encodeId=80bb2045854c7, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, objectType=article, longId=203570, objectId=632d2035e081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632d2035e081, replyNumber=0, likeNumber=91, createdTime=2021-07-30, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d2035e081, moduleTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632d2035e081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045851, encodeId=e79a2045851ac, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=62, createdTime=2020-07-02, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045850, encodeId=abe72045850de, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, objectType=article, longId=184991, objectId=d09c18499171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d09c18499171, replyNumber=0, likeNumber=61, createdTime=2020-11-03, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d09c18499171, moduleTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d09c18499171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045848, encodeId=9f8c20458489c, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）, objectType=article, longId=159821, objectId=c4251598216a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4251598216a, replyNumber=0, likeNumber=57, createdTime=2019-06-11, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4251598216a, moduleTitle=驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4251598216a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045849, encodeId=6049204584904, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌, objectType=article, longId=175747, objectId=f5121e574786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5121e574786, replyNumber=0, likeNumber=0, createdTime=2020-05-26, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5121e574786, moduleTitle=于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5121e574786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045846, encodeId=de2120458467b, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系, objectType=article, longId=150025, objectId=d10815002592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10815002592, replyNumber=0, likeNumber=72, createdTime=2019-02-13, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10815002592, moduleTitle=ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d10815002592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045842, encodeId=979c20458423d, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, objectType=article, longId=138096, objectId=5134138096d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5134138096d4, replyNumber=0, likeNumber=62, createdTime=2018-05-15, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5134138096d4, moduleTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5134138096d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045844, encodeId=808a204584490, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？, objectType=article, longId=149690, objectId=914b14969087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914b14969087, replyNumber=0, likeNumber=66, createdTime=2018-10-08, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914b14969087, moduleTitle=【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914b14969087)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045847, encodeId=cea9204584efe, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=ALK阳性非小细胞肺癌病例分享, objectType=article, longId=151632, objectId=3d4415163229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4415163229, replyNumber=0, likeNumber=79, createdTime=2019-07-05, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4415163229, moduleTitle=ALK阳性非小细胞肺癌病例分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d4415163229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045845, encodeId=9ddf20458453f, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, objectType=article, longId=149829, objectId=2dc21498290c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc21498290c, replyNumber=0, likeNumber=89, createdTime=2019-01-11, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc21498290c, moduleTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dc21498290c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045843, encodeId=2afc204584346, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌, objectType=article, longId=141979, objectId=3d0a1419e91d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d0a1419e91d, replyNumber=0, likeNumber=66, createdTime=2018-11-07, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d0a1419e91d, moduleTitle=CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d0a1419e91d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045841, encodeId=5bc8204584156, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=ROS1阳性非小细胞肺癌诊断病理专家共识, objectType=article, longId=136615, objectId=e43613661584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e43613661584, replyNumber=0, likeNumber=52, createdTime=2019-01-12, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e43613661584, moduleTitle=ROS1阳性非小细胞肺癌诊断病理专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e43613661584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045834, encodeId=f4bc204583424, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌, objectType=article, longId=100354, objectId=1e69100354f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e69100354f5, replyNumber=0, likeNumber=60, createdTime=2018-05-16, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e69100354f5, moduleTitle=诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e69100354f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045840, encodeId=7fda2045840f8, content=<a href='/topic/show?id=ecf49e5173d' target=_blank style='color:#2F92EE;'>#阳性非小细胞肺癌#</a>, objectTitle=NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著, objectType=article, longId=126225, objectId=afde12622574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afde12622574, replyNumber=0, likeNumber=61, createdTime=2018-02-24, rootId=0, userName=stfoxst, userId=1a19115, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afde12622574, moduleTitle=NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afde12622574)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阳性非小细胞肺癌

2020-05-29

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究

2021-10-19

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益

2021-08-14

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者

2021-04-30

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌

2021-06-30

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％

2021-03-02

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗

2021-02-10

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼

2021-07-30

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-07-02

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制

2020-11-03

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）

2019-06-11

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌

2020-05-26

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系

2019-02-13

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南

2018-05-15

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？

2018-10-08

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

ALK阳性非小细胞肺癌病例分享

2019-07-05

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率

2019-01-11

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌

2018-11-07

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

ROS1阳性非小细胞肺癌诊断病理专家共识

2019-01-12

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

诺华Zykadia获批一线治疗ALK阳性非小细胞肺癌

2018-05-16

stfoxst (审核中...)

前往app查看评论内容

#阳性非小细胞肺癌#

NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著

2018-02-24

科室
- - 订阅+
  - 更多科室
工具
服务